A post-marketing surveillance study to evaluate the real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors
Latest Information Update: 02 Dec 2019
At a glance
- Drugs Sunitinib (Primary)
- Indications Bone metastases; Glucagonoma; Insulinoma; Liver metastases; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 28 Nov 2019 New trial record